Nebivolol: a third-generation beta-blocker for hypertension
- PMID: 19393838
- DOI: 10.1016/j.clinthera.2009.03.007
Nebivolol: a third-generation beta-blocker for hypertension
Abstract
Background: Nebivolol is a third-generation beta(1)-selective beta-blocker that is approved for the treatment of hypertension.
Objective: This article reviews the clinical pharmacology of nebivolol and its efficacy and safety profile in clinical studies of hypertension (the US Food and Drug Administration-approved indication) and heart failure (off-label use).
Methods: Pertinent articles were identified through searches of MEDLINE and Current Contents from 1966 through December 15, 2008, using the terms nebivolol, drug interaction, pharmacokinetics, and pharmacology. The reference lists of the identified publications were reviewed for additional references. Abstracts presented at meetings of the American Heart Association and the American Society of Hypertension from 2006 through 2008 were also reviewed. All human clinical trials were included, regardless of design.
Results: Twelve published clinical trials were identified that evaluated the use of nebivolol in the management of hypertension; 1 was placebo controlled, 1 was placebo and active controlled, and 10 involved direct comparisons with other antihypertensive agents. Nebivolol was reported to be as effective in lowering blood pressure (BP) as other beta-blockers (atenolol and bisoprolol), angiotensin-converting enzyme inhibitors (lisinopril and enalapril), the angiotensin-receptor blocker telmisartan, and calcium channel blockers (nifedipine and amlodipine). No published studies were identified that evaluated the effect of nebivolol on long-term cardiovascular outcomes. In data from a study in heart failure, nebivolol was associated with a 14% reduction in all-cause mortality and cardiovascular hospitalization at 12 months (P < 0.05). In comparative clinical studies, nebivolol appeared to be well tolerated relative to the other antihypertensive agents studied. The most commonly reported adverse events with nebivolol were fatigue (4%-79%), headache (2%-24%), paresthesia (7%-13%), bradycardia (6%-11%), rhinitis (1%-7%), and dizziness (2%-5%). Because of differences in its pharmacologic properties, nebivolol may have potential advantages in patients who are unable to tolerate traditional beta-blockers (eg, patients with asthma or chronic obstructive pulmonary disease, or men who experience erectile dysfunction while taking antihypertensive therapy).
Conclusions: Nebivolol is a cardioselective beta-blocker that has been reported to be efficacious and well tolerated for achieving BP control in patients with hypertension. Preliminary evidence suggests a potential for reduced mortality in patients with heart failure.
Similar articles
-
Nebivolol: a third-generation beta-adrenergic blocker.Ann Pharmacother. 2006 Jul-Aug;40(7-8):1353-60. doi: 10.1345/aph.1G708. Epub 2006 Jul 5. Ann Pharmacother. 2006. PMID: 16822893 Review.
-
Nebivolol: new therapy update.Cardiol Rev. 2006 Sep-Oct;14(5):259-64. doi: 10.1097/01.crd.0000223651.03023.8e. Cardiol Rev. 2006. PMID: 16924166 Review.
-
The role of the new beta-blockers in treating cardiovascular disease.Am J Hypertens. 2005 Dec;18(12 Pt 2):169S-176S. doi: 10.1016/j.amjhyper.2005.09.009. Am J Hypertens. 2005. PMID: 16373195 Review.
-
[Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].Fortschr Med Orig. 2000 Jul 27;118 Suppl 2:77-82. Fortschr Med Orig. 2000. PMID: 15700490 German.
-
Beta-blockers in the management of hypertension: focus on nebivolol.Expert Rev Cardiovasc Ther. 2008 Apr;6(4):471-9. doi: 10.1586/14779072.6.4.471. Expert Rev Cardiovasc Ther. 2008. PMID: 18402537 Review.
Cited by
-
Development of Oral Tablets of Nebivolol with Improved Dissolution Properties, Based on Its Combinations with Cyclodextrins.Pharmaceutics. 2024 May 9;16(5):633. doi: 10.3390/pharmaceutics16050633. Pharmaceutics. 2024. PMID: 38794295 Free PMC article.
-
Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.Int J Mol Sci. 2022 Jun 10;23(12):6500. doi: 10.3390/ijms23126500. Int J Mol Sci. 2022. PMID: 35742943 Free PMC article. Review.
-
Identification of the New Metabolite of Nebivolol Using Liquid Chromatography Coupled with High-Resolution Mass Spectrometry and Chemometrics.Molecules. 2022 Jan 24;27(3):763. doi: 10.3390/molecules27030763. Molecules. 2022. PMID: 35164027 Free PMC article.
-
Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients: A Large-Scale Multicenter Observational Study.Hypertension. 2021 May 5;77(5):1528-1538. doi: 10.1161/HYPERTENSIONAHA.120.16402. Epub 2021 Mar 29. Hypertension. 2021. PMID: 33775125 Free PMC article.
-
A Critical Review of Nebivolol and its Fixed-Dose Combinations in the Treatment of Hypertension.Drugs. 2018 Nov;78(17):1783-1790. doi: 10.1007/s40265-018-0999-y. Drugs. 2018. PMID: 30426333
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical